Why bone density testing is important
Bone density testing serves as a critical diagnostic tool for assessing skeletal health and identifying conditions like osteoporosis before they lead to fractures. In Hong Kong, approximately 200,000 postmenopausal women suffer from osteoporosis, with hip fracture rates among elderly women being among the highest in Asia. These tests measure the mineral content in bones, providing valuable data about bone strength and fracture risk. Early detection through bone density assessment allows for timely intervention, including lifestyle modifications, nutritional adjustments, and medical treatments that can significantly reduce fracture risk. For individuals with specific risk factors—such as advanced age, family history of osteoporosis, long-term corticosteroid use, or low body weight—these tests become particularly crucial. The dexa exam represents the most advanced method in this diagnostic category, though other alternatives exist for different clinical situations.
Overview of different types of tests
Several diagnostic methods exist for evaluating bone density, each with distinct mechanisms and applications. The most common tests include Central DEXA (Dual-Energy X-ray Absorptiometry), Peripheral DEXA (pDEXA), Quantitative Ultrasound (QUS), and Quantitative Computed Tomography (QCT). Central DEXA measures bone mineral density (BMD) at the hip and spine—the most fracture-prone areas—and is considered the gold standard. Peripheral DEXA focuses on extremities like the wrist or heel, while QUS uses sound waves to assess bone density, typically at the heel or shin. QCT, though less common, provides three-dimensional density measurements but involves higher radiation exposure. Each test varies in accuracy, cost, radiation exposure, and accessibility, making them suitable for different clinical scenarios and patient populations.
How DEXA scan works
The DEXA scan operates using two low-energy X-ray beams that pass through bone and soft tissue simultaneously. By measuring the differential absorption of these beams, the machine calculates bone mineral density with remarkable precision. During the procedure, which typically lasts 10-20 minutes, patients lie fully clothed on a padded table while a scanning arm passes over their body. The radiation exposure is extremely low—approximately one-tenth of a standard chest X-ray—making it safe for repeated measurements. The results are presented as two scores: the T-score, which compares the patient's bone density to that of a healthy young adult of the same sex, and the Z-score, which compares it to age-matched averages. These scores help clinicians diagnose osteoporosis (T-score of -2.5 or lower) or osteopenia (T-score between -1.0 and -2.5). The dexa exam is particularly valuable because it can detect as little as 1-2% annual bone loss, enabling early intervention.
Advantages of DEXA scan (accuracy, precision)
DEXA scans offer unparalleled accuracy and precision in bone density measurement, making them the clinical gold standard. Their precision error is remarkably low at 1-2%, compared to 3-5% for other modalities. This high reproducibility allows clinicians to monitor subtle changes in bone density over time, essential for assessing treatment efficacy. The scan provides detailed measurements of both trabecular and cortical bone—the two primary bone types—particularly in the spine and hip where osteoporotic fractures most commonly occur. Additionally, modern DEXA machines can perform vertebral fracture assessments (VFA) and body composition analysis, adding clinical value beyond mere density measurement. The procedure's non-invasive nature, combined with its quick execution and minimal radiation exposure, makes it suitable for diverse populations, including postmenopausal women and patients requiring long-term monitoring.
Disadvantages of DEXA scan (cost, accessibility)
Despite its clinical superiority, the DEXA scan faces limitations in cost and accessibility. In Hong Kong, a private DEXA scan typically costs between HK$1,000 and HK$2,500, while public hospital waiting times can exceed six months for non-urgent cases. The equipment itself is expensive to purchase and maintain, requiring specialized facilities and trained technicians, which limits availability in rural areas or smaller clinics. Furthermore, the scan cannot distinguish between different types of bone tissue (trabecular vs. cortical) with the same resolution as some alternative methods, and it may be affected by artifacts from spinal degeneration, fractures, or surgical implants. These factors sometimes make peripheral testing methods more practical for initial screening, despite their limitations.
How QUS works
Quantitative Ultrasound (QUS) assesses bone health by measuring the speed of sound (SOS) and broadband ultrasound attenuation (BUA) as sound waves pass through bone. Typically performed on the heel, shin, or finger, the device calculates how quickly and strongly ultrasound signals travel through bone tissue. Denser bones transmit sound faster and with less attenuation than osteoporotic bones. The entire procedure is radiation-free, takes less than five minutes, and requires only a portable device about the size of a shoebox. Results are usually presented as a stiffness index or T-score equivalent, though these measurements are not directly comparable to DEXA T-scores. While QUS cannot diagnose osteoporosis according to formal WHO criteria, it effectively stratifies fracture risk, particularly in peripheral skeletal sites.
Advantages of QUS (portable, radiation-free)
QUS offers significant advantages in portability and safety, making it ideal for community screenings and primary care settings. The absence of ionizing radiation eliminates any radiation risk, allowing safe use in vulnerable populations including pregnant women and children. Its portability enables testing in remote villages, nursing homes, and even mobile health clinics, greatly improving accessibility for underserved communities. In Hong Kong, where population density creates logistical challenges for hospital-based testing, QUS devices have been deployed in community health centers for initial risk assessment. The procedure is quick, requires no special preparation, and costs approximately HK$300–HK$600—significantly less than a DEXA scan. These features make QUS an excellent tool for large-scale osteoporosis screening programs and preliminary risk assessment.
Disadvantages of QUS (less accurate than DEXA)
Despite its advantages, QUS has notable limitations in accuracy and diagnostic scope. It cannot measure bone density at the hip and spine—the most critical sites for osteoporotic fractures—and its precision error ranges from 3-5%, higher than DEXA's 1-2%. Results are influenced by factors such as skin temperature, soft tissue thickness, and operator technique, potentially reducing reliability. Unlike DEXA, QUS cannot monitor response to anti-osteoporosis medications with sufficient sensitivity, as changes in ultrasound parameters may not directly correlate with bone mineral density changes. Consequently, QUS is not recommended for definitive diagnosis or treatment monitoring but serves best as a pre-screening tool to identify patients who require further evaluation with a dexa exam.
How pDEXA works
Peripheral DEXA (pDEXA) operates on the same dual-energy X-ray principle as central DEXA but focuses on peripheral sites like the wrist, heel, or finger. The device is smaller, often portable, and uses even lower radiation doses than central DEXA. During the procedure, the patient places their forearm, heel, or finger in the device, which scans for 2-5 minutes to calculate bone mineral density. While pDEXA provides actual BMD measurements (in g/cm²) and T-scores comparable to central DEXA for the measured site, it does not assess the clinically critical spine and hip. Nevertheless, it offers a reasonable approximation of overall skeletal health, particularly in settings where central DEXA is unavailable.
Advantages of pDEXA (lower cost, convenient)
pDEXA combines some of the accuracy of DEXA technology with greater convenience and lower cost. In Hong Kong, pDEXA tests typically cost HK$400–HK$800—about half the price of a central DEXA scan. The equipment is compact enough for use in primary care clinics, pharmacies, and even mobile health units, reducing travel burdens for elderly patients. The rapid testing time and minimal preparation required make it efficient for high-throughput screening. For patients with contraindications to central DEXA (e.g., recent contrast imaging or metal implants), pDEXA offers a viable alternative. Its ability to provide quantitative BMD measurements—unlike QUS—makes it particularly useful for initial assessment where central DEXA is inaccessible.
Disadvantages of pDEXA (only measures bone density in extremities)
The primary limitation of pDEXA is its restricted measurement sites. Since it only assesses peripheral bones, it may miss early osteoporotic changes in the spine and hip, which often precede peripheral bone loss. Discordance between peripheral and central measurements occurs in approximately 15-20% of cases, potentially leading to false reassurance or unnecessary concern. Additionally, pDEXA cannot monitor treatment response effectively, as medications for osteoporosis primarily affect axial rather than peripheral skeleton. Thus, while pDEXA serves as a useful screening tool, abnormal results usually require confirmation with a central dexa exam for accurate diagnosis and management planning.
Factors to consider (risk factors, medical history)
Selecting the appropriate bone density test depends on multiple factors:
- Age and sex: Postmenopausal women and men over 70 are prime candidates for DEXA
- Fracture history: Previous fragility fractures warrant central DEXA
- Medications: Long-term steroid use (>3 months) requires baseline DEXA
- Medical conditions: Rheumatoid arthritis, hyperthyroidism, or malabsorption syndromes increase risk
- Family history: Parental hip fracture doubles personal risk
- Lifestyle factors: Smoking, excessive alcohol, and low physical activity contribute to bone loss
In Hong Kong's ethnic context, studies show Chinese women have lower hip BMD but similar fracture risks compared to Caucasians, necessitating population-specific assessment tools.
Discussing options with your doctor
Consultation with a healthcare provider ensures test selection aligns with individual risk profiles. Patients should discuss:
- Their complete medical history and medication list
- Any previous fractures or height loss
- Accessibility constraints (e.g., mobility issues)
- Cost considerations and insurance coverage
- Preferences regarding radiation exposure
Doctors may recommend starting with QUS or pDEXA for low-risk individuals, while proceeding directly to DEXA for high-risk patients. In Hong Kong's public healthcare system, referral guidelines prioritize DEXA for those with specific risk factors, while private healthcare offers more flexible options.
When is DEXA scan recommended?
The dexa exam is specifically indicated for:
- All women aged 65+ and men aged 70+
- Postmenopausal women under 65 with risk factors
- Adults with fragility fractures after age 50
- Patients on long-term glucocorticoid therapy (≥5 mg prednisone daily for ≥3 months)
- Those with conditions associated with bone loss (e.g., hyperparathyroidism, celiac disease)
- Monitoring osteoporosis treatment efficacy (every 1-2 years)
- Anyone considering osteoporosis medication based on risk assessment
Hong Kong Hospital Authority guidelines recommend baseline DEXA for these groups, with follow-up scans based on initial results and treatment response. The superior accuracy and central skeletal assessment make DEXA indispensable for definitive diagnosis and management.
